Telescope Innovations Corp · CSE:TELI
Telescope Innovations — Investor Presentation (March 2023)
27 slides from Telescope Innovations's investor presentation, Mar 1, 2023
Slide 1: Telescope Innovations
Slide 2: Disclaimer and forward-looking statements
TELI (CSE) The Presentation is intended for educational and informational purposes only and does not replace independent professional judgment. Statements of fact and opinions expressed are those of the participants individually. The information is not designed to provide financial, tax planning, acc
Slide 3: Our Company
TELI (CSE) OUR COMPANY TELIF (OTCQB) Telescope Innovations Corp. is a specialty Contract Research Organization (CRO). We compresses R&D timelines and accelerate the deployment of chemical and pharmaceutical products to the market. TELI (CSE) TELIF (OTCQB) telescopeinnovations.com 3
Slide 4: Who We Are
TELI (CSE) WHO WE ARE Our award-winning scientific leadership includes a 2-time Nobel Prize Winner in Chemistry. TELIF (OTCQB) We have collectively authored over 450 academic publications and 34 patents. PROF. JASON HEIN DR. BARRY SHARPLESS DR. JEFF SHERMAN PALOMA PRIETO SHAD GRUNERT DR. LARS YUNKER
Slide 5: Our Board of Directors
TELI (CSE) OUR BOARD OF DIRECTORS Our directors bring over 80 years combined experience in building technology companies and TELIF (OTCQB) successfully managing companies in the capital markets. DR. ANDY ROBINSON ROBERT MINTAK ALI PEJMAN PROF. JASON HEIN HENRY DUBINA An experienced scientist with a
Slide 6: CROs Provide High Value to Pharma, Biotech & Chemical Industries
TELI (CSE) CROs PROVIDE HIGH VALUE TO PHARMA, BIOTECH, & CHEMICAL INDUSTRIES TELIF (OTCQB) REDUCE R&D COSTS BY ~15% Specialized labour, facilities/infrastructure, operating costs, etc. Contract Research Organizations provide crucial research RAPID TURN-AROUND TIME and developmentDiscovery services $
Slide 7: How Big Is the Opportunity? Market by Sector
TELI (CSE) HOW BIG IS THE OPPORTUNITY? GLOBAL CRO MARKET SIZE* 2021 CRO MARKET BREAKDOWN TELIF (OTCQB) BY SECTOR* $84.9 B 80 Lab services Regulatory Discovery services $2.53 B 60 $53.9 B Early Billions USD development Preclinical 40 $6.74 B $2.53 B 6.7% CAGR Clinical research services Chemistry, 20
Slide 8: How Big Is the Opportunity? Market by Geography
TELI (CSE) HOW BIG IS THE OPPORTUNITY? GLOBAL CRO MARKET SIZE* 2021 CRO MARKET BREAKDOWN TELIF (OTCQB) BY GEOGRAPHY* $84.9 B 80 NORTH AMERICA 43% 60 $53.9 B Billions USD 40 6.7% CAGR TELESCOPE INNOVATIONS 20 EUROPE 28% is already active in these sectors 0 ASIA/PACIFIC 14% 2021 ‘22 ‘23 ‘24 ‘25 ‘26 ‘2
Slide 9: How Telescope Succeeds in the CRO Ecosystem
TELI (CSE) HOW TELESCOPE SUCCEEDS IN THE CRO ECOSYSTEM AUTOMATION PRODUCTS TELIF (OTCQB) SALES & SUPPORT REVENUE • Proprietary analytical methods • Artificial intelligence tools Our world-class scientific team deploys RESEARCH SERVICES advanced robotics and CONTRACT REVENUE artificial intelligence • Fa
Slide 10: Strategic Partners and Clients
TELI (CSE) STRATEGIC PARTNERS AND CLIENTS TELIF (OTCQB) SCIENTIFIC PHARMACEUTICAL MINING ENGINEERING GOVERNMENT INSTRUMENTATION COMPANIES COMPANIES COMPANIES AND ACADEMIA COMPANIES telescopeinnovations.com 10
Slide 11: Research Services
SERVICES RESEARCH TELIF (OTCQB) TELI (CSE)
Slide 12: Industrial Research Services
TELI (CSE) INDUSTRIAL RESEARCH SERVICES TELIF (OTCQB) We resolve bottlenecks and inefficiencies in chemical and pharmaceutical manufacturing. OUR RESULTS MARKETS & APPLICATIONS OUR DIFFERENTIATORS Pharmaceutical/ Robotics and Fast process scale-up chemical process flexible automation R&D Efficient Mate
Slide 13: Project Highlight: Automation for Pharmaceutical R&D
TELI (CSE) PROJECT HIGHLIGHT: AUTOMATION FOR TELIF (OTCQB) PHARMACEUTICAL R&D Built proof-of-concept robotic workflow in 4 months We completed a feasibility research project funded by Pfizer to build automated solutions for pharmaceutical process development. Identified pathways to accelerate pharmaceu
Slide 14: Project Highlight: Clean Energy Process Research
TELI (CSE) PROJECT HIGHLIGHT: CLEAN ENERGY PROCESS RESEARCH TELIF (OTCQB) We are optimizing lithium refinement technology in partnership with Standard Lithium (SLI). Our improvements enable higher extraction efficiency of low-grade brines to produce battery-quality materials. We are also exploring the
Slide 15: Project Highlight: Big Pharma Manufacturing
TELI (CSE) PROJECT HIGHLIGHT: BIG PHARMA MANUFACTURING We helped resolve a critical manufacturing issue for a globally-leading pharmaceutical company*. TELIF (OTCQB) THE THEIR OUR CLIENT PROBLEM SOLUTION Massive pharmaceutical Unexplained 80% drop in synthetic We leveraged unique analytical tools to
Slide 16: Products: Automation
PRODUCTS AUTOMATION TELIF (OTCQB) TELI (CSE)
Slide 17: Products
TELI (CSE) PRODUCTS TELIF (OTCQB) DILC was funded & developed in response to a specific request by Enabling Technologies TM Consortium (ETC). telescopeinnovations.com 17
Slide 18: Products
TELI (CSE) PRODUCTS TELIF (OTCQB) DILC was funded & developed in response to a specific request by Enabling Technologies TM Consortium (ETC). telescopeinnovations.com 18
Slide 19: DILC Product: Where We Are Today
DILCTM PRODUCT: WHERE WE ARE TODAY Installed units Active prospects telescopeinnovations.com 19
Slide 20: Global Process Analytical Technology (PAT) Market
TELI (CSE) GLOBAL PROCESS ANALYTICAL TECHNOLOGY (PAT) MARKET* KEY TELIF (OTCQB) ● Massive, increasing R&D spending in pharma and biotech DRIVERS ● Need for automation and quality control in pharmaceutical manufacturing GLOBAL MARKET SIZE 2021 BREAKDOWN BY TECHNIQUE $4.3 B DILCTM addresses 4 this mar
Slide 21: Intellectual Property Licensing
TELI (CSE) TELIF (OTCQB) INTELLECTUAL PROPERTY LICENSING
Slide 22: Project Highlight: Fast-Track Synthesis of Scheduled Compounds
TELI (CSE) PROJECT HIGHLIGHT: FAST-TRACK SYNTHESIS OF SCHEDULED COMPOUNDS TELIF (OTCQB) THE THEIR OUR CLIENT PROBLEM SOLUTION A manufacturer must deliver Manufacturer has never made these We develop an efficient process for a new, scheduled compounds contract research fee compounds for clinical trial
Slide 23: Business Case & Shareholder Value Proposition
TELI (CSE) TELIF (OTCQB) BUSINESS CASE & SHAREHOLDER VALUE PROPOSITION
Slide 24: Building a Successful Track Record
TELI (CSE) BUILDING A SUCCESSFUL TRACK RECORD TELIF (OTCQB) 5 major pharma Product launch contracts Telescope contracts Telescope companies have installed beta DILC products First contract for Lab set up in Vancouver, BC Telescope CRO Repeat business contracts Telescope contracts Telescope Jun Sep N
Slide 25: Financial Status
TELI (CSE) FINANCIAL STATUS STOCK TICKER SYMBOLS TELIF (OTCQB) TELI (CSE), TELIF(OTCQB) CAPITAL STRUCTURE PRICE NUMBER February 22, 2022 Average Shares issued 53,665,569 Stock options $ 0.83 3,775,000 Warrants $ 0.75 2,439, 749 Fully Diluted Share Position 59,880,318 Shares held by Directors / Office
Slide 26: Summarizing the Opportunity
TELI (CSE) SUMMARIZING THE OPPORTUNITY TELIF (OTCQB) STRONG BOARD OF DIRECTORS & KEY ADVISORS DYNAMIC, INTERDISCIPLINARY TEAM AUTOMATION PRODUCTS RESEARCH SERVICES INTELLECTUAL PROPERTY DEVELOPMENT & LICENSING HIGH-GROWTH ADDRESSABLE MARKETS telescopeinnovations.com 26
Slide 27: Thank You
THANK YOU Contact: [email protected]
Telescope Innovations — Investor Presentation (March 2023) on 6ix